Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates

Michiyo Deushi, Mizuko Osaka, Kaku Nakano, Kyoichi Osada, Kensuke Egashira, Masayuki Yoshida

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)


    Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1-like1 inhibitor, ezetimibe (Ez). Macaca fascicularis (5-year-old males) were fed either regular cholesterol + high-fat diet (control-HFD) or oxysterols + high-fat diet (ox-HFD; with 0.015% of oxysterols cholesterol) for 24 weeks. Compared with control-HFD, ox-HFD did not affect plasma lipid levels, but it did affect hepatic lipid levels [total cholesterol, 40.9 mg·g−1 (ox-HFD) versus 3.2 (control-HFD) mg·g−1; triglycerides, 28.0 (ox-HFD) versus 5.7 (control-HFD) mg·g−1]. Ox-HFD increased lipid accumulation as well as recruitment of inflammatory cells when compared to control-HFD. We then examined the effects of Ez, 0.2 mg·kg−1·day−1 for 12 weeks. In addition to a significant reduction in dyslipidemia, Ez alleviated biochemical and pathological aspects of steatosis. Dietary oxysterols aggravate steatosis in nonhuman primates. Treatment with Ez may be a novel therapeutic approach to NAFLD by alleviating dyslipidemia.

    Original languageEnglish
    Pages (from-to)1008-1015
    Number of pages8
    JournalFEBS Open Bio
    Issue number10
    Publication statusPublished - Oct 1 2016

    All Science Journal Classification (ASJC) codes

    • Biochemistry, Genetics and Molecular Biology(all)


    Dive into the research topics of 'Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates'. Together they form a unique fingerprint.

    Cite this